Phase IIIMitochondrial Peptide
Compound 61466
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061466
Risk Class
MODERATE
Last Audit
Feb 23, 2108
Research Abstract
Mitochondrial Peptide candidate engineered for cognitive resilience initiatives with automated dossier coverage.
Compound 61466 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for cognitive resilience and neuroprotection.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061466 with updates logged 2108-02-23.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cognitive resilienceNeuroprotection
Nomenclature
CX-61466Mitochondrial Peptide Program 61466
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061466
- [2] Operations Pulse • Mitochondrial Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61466